Summary

On 11 March 2020, the World Health Organization declared COVID-19 a global pandemic, and the disease now affects nearly every country and region. Caused by SARS-CoV-2, COVID-19 continues nearly 18 months later to present significant challenges to health systems and public health in both hemispheres, as well as the economies of every country. The morbidity and mortality of the infection caused by SARS-CoV-2 has been significant, and various waves of disease outbreaks initially overwhelmed many hospitals and clinics and continue to do so in many countries. This influences everyone, and public health countermeasures have been dramatic in terms of their impact on employment, social systems, and mental health. This entry collection aims to gather diverse fields about COVID-19, including in epidemiology, public health, medicine, genetics, systems biology, informatics, data science, engineering, sociology, anthropology, nursing, environmental studies, statistics, and psychology.

Expand All
Entries
Topic Review
COVID-19 and Migrant/Refugee Health
Against a background where the world has witnessed the largest numbers of migrants in history, the advent of the COVID-19 pandemic has stretched the capacities of countries and of aid, health and relief organizations, from global to local levels, to meet the human rights and pressing needs of migrants and refugees for access to health care and to public health measures needed to protect them from the pandemic. 
  • 738
  • 14 Dec 2021
Topic Review
Neck Circumference Predicts Mortality in COVID-19 patients
A large neck is associated with a premorbid increased proinflammatory and prothrombotic status, which makes the patient more prone to progress toward an unfavorable outcome. Neck circumference is an independent predictor for mortality in our hospitalized COVID-19 patients with respiratory failure and should complement the baseline evaluation of such patients.
  • 740
  • 11 Dec 2021
Topic Review
Colorectal Cancer Screening During the COVID-19 Pandemic
Colonoscopy procedure has been the key screening method to detect colorectal cancer (CRC). As a fatal disease, CRC needs early detection. The COVID-19 (coronavirus disease 2019) pandemic caused screening tests (mainly colonoscopy) to be halted and delayed. At the same time, the use of other screening tests like fecal immunochemical testing (FIT) increased.  
  • 966
  • 15 Dec 2021
Topic Review
MALDI MS-Based Investigations Targeting SARS-CoV-2
The urgent need to fight the COVID-19 pandemic has impressively stimulated the efforts of the international scientific community, providing an extraordinary wealth of studies. Improving the current laboratory testing methods and developing new rapid and reliable diagnostic approaches might be useful in managing contact tracing in the fight against both the original SARS-CoV-2 strain and the new, potentially fast-spreading CoV-2 variants. Mass Spectrometry (MS)-based testing methods and more specifically MALDI-MS have demonstrated without any doubt the great potential to overcome many unresolved analytical challenges arising from currently used laboratory testing assays, becoming an effective proteomic tool in several applications, including pathogen identification. With the aim of highlighting the challenges and opportunities that derive from MALDI-based approaches for the detection of SARS-CoV-2 and its variants, we extensively examined the most promising proofs of concept for MALDI studies related to the COVID-19 outbreak.
  • 1.3K
  • 13 Dec 2021
Topic Review
COVID-19 Advanced Therapies
The coronavirus disease 2019 (COVID-19) pandemic, related to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden and substantial burden in public health due to an enormous increase in hospitalizations for pneumonia with the multiorgan disease. Treatment for individuals with COVID-19 includes best practices for supportive management of acute hypoxic respiratory failure. Emerging data indicate that dexamethasone therapy reduces 28-day mortality in patients requiring supplemental oxygen compared with usual care, and ongoing trials are testing the efficacy of antiviral therapies, immune modulators and anticoagulants in the prevention of disease progression and complications, while monoclonal antibodies and hyperimmune globulin may provide additional preventive strategies. Consensus suggestions can standardize care, thereby improving outcomes and facilitating future research.
  • 1.0K
  • 13 Dec 2021
Topic Review
SARS-CoV-2 Vaccine Hesitancy
The underlying factors of vaccine hesitancy are complex and context-specific, varying across time and socio-demographic variables. Vaccine hesitancy can also be influenced by other factors such as health inequalities, socioeconomic disadvantages, systemic racism, and level of exposure to misinformation online, with some factors being more dominant in certain countries than others. Therefore, strategies tailored to cultures and socio-psychological factors need to be developed to reduce vaccine hesitancy and aid informed decision-making. 
  • 1.0K
  • 13 Dec 2021
Topic Review
Views on Vaccination against COVID-19 Virus
Mass immunization of the citizens of the Republic of Serbia began in January 2021. Information on the significance, manner, advantages and consequences of this process was intensively distributed through all communication channels, with the media playing a key role. According to the data of the official institutions for the public health of Serbia, by July 2021 the lowest percentage of vaccinated population was among those between the ages of 18 and 24—only 15% of this demographic had received the vaccine by this point.
  • 1.0K
  • 08 Dec 2021
Topic Review
Circulating Leukocytes in People Mildly Infected by SARS-CoV-2
Mild SARS-CoV-2 infections (n = 22), compared to those that had recovered from other mild respiratory infections (n = 11). Individuals who had experienced mild SARS-CoV-2 infections had elevated levels of C-reactive protein 1–3 months after symptom onset, and changes in phenotype and function of circulating T-cells that were not apparent in individuals 6–9 months post-symptom onset. Markers of monocyte activation, and expression of adherence and chemokine receptors indicative of altered migratory capacity, were also higher at 1–3 months post-infection in individuals who had mild SARS-CoV-2, but these were no longer elevated by 6–9 months post-infection. Perhaps most surprisingly, significantly more T-cells could be activated by polyclonal stimulation in individuals who had recently experienced a mild SARS-CoV-2, infection compared to individuals with other recent respiratory infections. These data are indicative of prolonged immune activation and systemic inflammation that persists for at least three months after mild or asymptomatic SARS-CoV-2 infections. 
  • 707
  • 07 Dec 2021
Topic Review
Vitamin C and Multiple Pathophysiological Stages of COVID-19
Vitamin C (ascorbic acid, AA) is an essential nutrient with many biological roles that have been proven to play an important part in immune function; it serves as an antioxidant, an anti-viral, and exerts anti-thrombotic effects among many other physiological benefits. Research has proven that AA at pharmacological doses can be beneficial to patients with acute respiratory distress syndrome (ARDS) and other respiratory illnesses, including sepsis. In addition, High-Dose Intravenous Vitamin C (HDIVC) has proven to be effective in patients with different viral diseases, such as influenza, chikungunya, Zika, and dengue. Moreover, HDIVC has been demonstrated to be very safe. Regarding COVID-19, vitamin C in addition to its antiviral properties, it can suppress the cytokine storm, reduce thrombotic complications, and diminish alveolar and vascular damage, among other benefits.
  • 1.1K
  • 07 Dec 2021
Topic Review
Prime-Boost COVID-19 Vaccination against SARS-CoV-2
The types of these vaccines include two recombinant adenovirus vaccines (ChAdOx1-S and Ad26.COV2-S), one heterologous recombinant adenovirus vaccine (Gam-COVID-Vac), two mRNA vaccines (BNT162b2 and mRNA-1273), two inactivated virus vaccines (BBIBP-CorV and CoronaVac), and one recombinant protein vaccine (NVX-CoV2373).
  • 961
  • 07 Dec 2021
  • Page
  • of
  • 74

Other Entry Collections

>>